Target intelligence / Profile preview

microRNA 4458 (miR-4458)

Target
miR-4458
Molecular classification
microRNA (miRNA), Other (non-coding RNA gene product)
01

Overview

microRNA 4458 (miR-4458) is a small, non-coding RNA molecule belonging to the microRNA family that regulates post-transcriptional gene expression by binding to target mRNA sequences, typically reducing their expression. It acts as a tumor suppressor in several cancer types (notably lung, colon, and hepatocellular carcinoma) by inhibiting key oncogenes including IGF1R, CCND1, and Lin28B. Increased expression of miR-4458 represses cancer cell proliferation, induces cell cycle arrest at G0/G1 phase, and promotes apoptosis, while reduced levels are associated with poor clinical outcomes in lung cancer. Its modulation has potential as both a therapeutic strategy and diagnostic/prognostic biomarker in oncology, although there are currently no approved drugs directly targeting this miRNA, and therapeutic targeting is challenged by specificity and delivery issues common to miRNA-based interventions.

Other names
miR-4458hsa-miR-4458MIR4458mir-4458
02

Mechanism of action

miRNA mimics (can restore tumor suppressor function); miRNA inhibitors/anti-miRs (can inhibit miR-4458 expression); Indirect modulation of gene expression via downstream targets such as IGF1R, CCND1, Lin28B

03

Biological functions

Negative regulation of cell proliferationInduction of cell cycle arrest at G0/G1Promotion of apoptosisRegulation of gene expression at post-transcriptional level via binding to 3′UTRs of target mRNAsTumor suppressor function
04

Disease associations

Cancer (tumor suppressor in lung cancer, hepatocellular carcinoma, colon cancer)Potential biomarker for hepatocellular carcinoma prognosisPossible involvement in glycolysis and lactate production in colon cancer
05

Safety considerations

Modulating miRNAs could influence multiple cellular pathways, raising risk of off-target effects and unintended tissue toxicity.Lack of specificity and delivery challenges for RNA-based therapeutics.
06

Interacting drugs

None currently documented; small-molecule or oligonucleotide modulators are under research, but no approved drugs target miR-4458 directly.
07

Biomarkers

Low expression of miR-4458 as a predictive biomarker for poor survival in lung cancer patientsmiR-4458 expression levels potentially useful for patient selection or efficacy monitoring in hepatocellular carcinoma

Beyond the preview

Go deeper on microRNA 4458 (miR-4458).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA 4458 (miR-4458).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call